

=> b casre

FILE 'CASREACT' ENTERED AT 14:32:10 ON 07 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 2 Jun 2007 VOL 146 ISS 24

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*   CASREACT now has more than 12 million reactions
*
*****
```


Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.



=> d que sta l8

L3 STR


RRT



PRO



Ak~CN
 @38 39



VAR G1=S/N/CN/AK/X/38/26/41

REP G2=(1-4) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE



L5 352 SEA FILE=CASREACT SSS FUL L3 (2701 REACTIONS)

L6 STR


RRT



PRO



AK~CN
@38 39



VAR G1=S/N/CN/AK/X/38/26/41

REP G2=(1-4) C

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1

CONNECT IS E2 RC AT 2

CONNECT IS E2 RC AT 3

CONNECT IS E2 RC AT 5

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L8 24 SEA FILE=CASREACT SUB=L5 SSS FUL L6 (38 REACTIONS)

100.0% DONE 2701 VERIFIED

38 HIT RXNS

24 DOCS

SEARCH TIME: 00.00.01

=> d bib abs crd l8 tot

L8 ANSWER 1 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 145:292716 CASREACT

TI Process for preparation of sodium isophthalic acid 5-sulfonate

IN Liu, Xusi; Sui, Fulong

PA Dongying Xuye Chemical Co., Ltd., Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 5pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN---1821224	A	20060823	CN 2006-10043229	20060320

PRAI CN 2006-10043229 20060320

AB The method for preparing sodium isophthalic acid 5-sulfonate comprises sulfonating isophthalic acid with fuming sulfuric acid (molar ratio 1:1.5) at 150-200 °C for 5-10 h, neutralizing with base at 100-130 °C under stirring, centrifuging to obtain the product, recrystg. with hot water (60-100 °C) together with decolorizing agent and

oxidant (e.g. hydrogen peroxide), and recrystg. for a second time. The mother liquid after precipitating and centrifuging is extracted with toluene and acid, then neutralized with base. The yield is above 80%, and the mother liquid is recycled in a close system, and thus both pollution and cost are reduced.

RX(1) OF 1



NOTE: regioselective, fuming sulfuric acid used in stage 1, NaOH, Na₂CO₃, or NaHCO₃ used in stage 2
 CON: STAGE(1) 5 - 10 hours, 150 - 220 deg C
 STAGE(2) 100 - 130 deg C; 100 deg C -> room temperature

L8 ANSWER 2 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 141:424031 CASREACT

TI Preparation of sulfo-substituted aromatic carboxylic acid alkyl esters and their salts with high esterification yield

IN Ogata, Eiji; Yanase, Norio; Kitahara, Takayuki

PA Konishi Kagaku Kogyo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP2004331527	A	20041125	2003JP-0126844	20030502
PRAI	2003JP-0126844		20030502		


AB Title compds., useful as modifiers for polyesters, are prepared by esterification of sulfo-substituted aromatic carboxylic acids with lower alcs. while precipitating the crystals of the resulting esters, optionally followed by neutralization of the crystals. Thus, sulfonation of isophthalic acid gave 5-sulfoisophthalic acid hydrate, which was refluxed in o-dichlorobenzene to remove the water, esterified with MeOH at from 90° to 30°, and adjusted to pH 7 to give di-Me 5-sodiosulfoisophthalate with 83% overall yield.

RX(1) OF 6



NOTE: alternative prepn. shown
 CON: 2 hours, 190 deg C

RX(5) OF 6 - 2 STEPS



NOTE: 1) alternative prepn. shown

CON: STEP(1.1) 2 hours, 190 deg C

STEP(2.1) 1 hour, 90 deg C; 5 hours, 30 deg C

L8 ANSWER 3 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 141:277358 CASREACT

TI Preparation of high-purity dialkyl 5-bromoisophthalates

IN Fujimoto, Masaki; Noji, Kazuaki

PA Sanko Chemical Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP2004262778	A	20040924	2003JP-0052340	20030228
PRAI	2003JP-0052340		20030228		

AB Title compds. are prepared by cooling alc. solns. containing crude dialkyl 5-bromoisophthalates for crystallization. Thus, 5-bromoisophthalic acid (I) was brominated with Br to give a reaction mixture (I 6.2%, 5-bromoisophthalic acid 84.7%, 4-bromoisophthalic acid 0.3%, 4,5-dibromoisophthalic acid 5.2%), which was refluxed with MeOH in the presence of H₂SO₄, condensed, cooled, kept at room temperature for 3 h, filtered, and washed with MeOH to give di-Me 5-bromoisophthalate with purity 99.1%.


RX(1) OF 5



CON: STAGE(1) 30 - 35 deg C; 30 - 35 deg C -> 60 deg C


STAGE(2) 5 hours, 60 deg C; 24 hours, 60 deg C

RX(4) OF 5 - 2 STEPS



CON: STEP(1.1) 30 - 35 deg C; 30 - 35 deg C -> 60 deg C
STEP(1.2) 5 hours, 60 deg C; 24 hours, 60 deg C
STEP(2) 24 hours, reflux


RX(5) OF 5 - 2 STEPS



CON: STEP(1.1) 30 - 35 deg C; 30 - 35 deg C -> 60 deg C
STEP(1.2) 5 hours, 60 deg C; 24 hours, 60 deg C
STEP(2) 24 hours, reflux

LB ANSWER 4 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
AN 140:16533 CASREACT
TI Bromination by means of sodium monobromoisocyanurate (SMBI)
AU Okada, Yukihiro; Yokozawa, Masanori; Akiba, Miwa; Oishi, Kazuhiko; Okawa, Kyoji; Akeboshi, Tomohiro; Kawamura, Yasuo; Inokuma, Seiichi; Nakamura, Yosuke; Nishimura, Jun
CS Department of Chemistry, Gunma University, Kiryu, 376-8515, Japan
SO Organic & Biomolecular Chemistry (2003), 1(14), 2506-2511
CODEN: OBCRAK; ISSN: 1477-0520
PB Royal Society of Chemistry
DT Journal
LA English
AB A variety of aromatic compds. with both activating and deactivating substituents were brominated with sodium monobromoisocyanurate (I) in Et₂O, Et₂O-MeSO₃H, F₃CCO₂H, or H₂SO₄. Thus PhNO₂ was conveniently brominated in H₂SO₄, C₆H₇ was readily monobrominated in Et₂O-MeSO₃H, and PhOH was selectively brominated at the ortho position under mild conditions in refluxing Et₂O. With substituents that are easily protonated, F₃CCO₂H may be employed as solvent in the reaction with I; in contrast NBS was ineffective in F₃CCO₂H. This renders I a superior reagent relative to NBS. In addition to aroms., alkenes, ketones and esters were also brominated with I. Di-Et malonate was brominated with I and then subjected to a Bingel reaction with NaH to afford the desired methanofullerene in reasonable yield.

RX(7) OF 47




NOTE: regioselective, green chem.-reagent
 CON: 12 hours, room temperature -> 40 deg C

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 139:118987 CASREACT
 TI Synthesis of sodium dimethyl 5-sulfoisophthalate
 AU Li, Guo-qiang; Tang, Xu-li; Wen, Li-rong; Yu, Yong-liang
 CS Institute of Chemical and Molecular Technology, Qingdao University of
 Science and Technology, Qingdao, Shandong, 266042, Peop. Rep. China
 SO Jingxi Huagong (2003), 20(1), 50-52
 CODEN: JIHUFJ; ISSN: 1003-5214
 PB Jingxi Huagong Bianjibu
 DT Journal
 LA Chinese
 AB The title compound(sodium di-Me 5-sulfoisophthalate, SIPM) was prepared from
 isophthalic acid (IPA), using w(SO₃) = 30% oleum as sulfonating agent. By
 orthogonal exptl. design method, the optimum sulfonation reaction
 conditions were determined:n(IPA):n(SO₃) = 1.00:1.15 at 185° for 4.5 h.
 By HPLC method, the neutralization process was controlled at pH value of
 5.0. Yield of SIPM was 85.2% and the purity was w(SIPM) = 99.5%.
 Specifications of the product conformed with the standard of Du Pont Co.

RX(1) OF 1



NOTE: optimization study
 CON: STAGE(1) room temperature -> 185 deg C; 4.5 hours, 185 deg C
 STAGE(2) 4 hours, reflux; reflux -> room temperature
 STAGE(3) neutralized

L8 ANSWER 6 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 138:271391 CASREACT
 TI Process for the preparation of 5-aminoisophthalic acid by sequential
 bromination and ammonolysis of isophthalic acid.
 IN Gelmont, Mark
 PA Bromine Compounds Ltd., Israel

SO Israeli, 15 pp.

CODEN: ISXXAQ

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IL----118972	A	20000928	1996IL-0118972	19960729

PRAI 1996IL-0118972 19960729


AB 5-Aminoisophthalic acid was prepared by sequential bromination and ammonolysis of isophthalic acid. Thus, isophthalic acid in 65% oleum at 103-106° was treated dropwise with Br₂ over 4 h; heating and stirring were continued for 2 h to give a crude precipitate comprising 51% crude 5-bromoisophthalic acid and 49% oleum. This was autoclaved with NH₃ and cat. CuSO₄·5H₂O at 140° for 3 h to give 77% 5-aminoisophthalic acid.

RX(1) OF 3



CON: STAGE(1) room temperature -> 106 deg C; 4 hours; 2 hours

RX(3) OF 3 - 2 STEPS



NOTE: 2) optimization study

CON: STEP(1.1) room temperature -> 106 deg C; 4 hours; 2 hours

STEP(2.1) 3.5 hours, room temperature -> 140 deg C;

140 deg C -> 30 deg C

L8 ANSWER 7 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 137:249482 CASREACT

TI A New Route for the Preparation of 5-Hydroxyisophthalic Acid

AU Gelmont, Mark; Oren, Jakob

CS IMI (TAMI) Institute for Research and Development Ltd., Haifa Bay, 26111, Israel

SO Organic Process Research & Development (2002), 6(5), 591-596

CODEN: OPRDFK; ISSN: 1083-6160


PB American Chemical Society

DT Journal

LA English

AB A new, simple and practical, two-stage process for the preparation of 5-hydroxyisophthalic acid (5-HIPA) from isophthalic acid is described. In the first stage, isophthalic acid is brominated by bromine in oleum, in the presence of an iodine catalyst, to give crude 5-bromoisophthalic acid (5-BIPA). In the second stage the crude 5-BIPA is hydrolyzed with aqueous NaOH, in the presence of a copper catalyst, to give crude 5-HIPA, with a purity of ca. 98%. Both stages of the process were optimized. A single crystallization of the crude 5-HIPA from water gives the product in a purity of more than 99%. The overall yield of pure 5-HIPA is 65-70%.

RX(1) OF 4




NOTE: regioselective, overall yield 50%, 91% of product was 5-bromoisophthalic acid, 6% combined yield of dibromoisophthalic acid, other products also detected, alternate workups also described, optimization study, optimized on temp., catalyst, amt. of catalyst, amt. of oleum, workup


RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 137:200992 CASREACT
 TI A non-rotatory isomerization path in ethene derivatives? Investigation of a stilbenophane and protonated azobenzenophanes ("pseudo-stilbenophanes")
 AU Rau, Hermann; Waldner, Isabella
 CS FG Physikalische Chemie, Universitaet Hohenheim, Stuttgart, 70593, Germany
 SO Physical Chemistry Chemical Physics (2002), 4(10), 1776-1780
 CODEN: PPCPFQ; ISSN: 1463-9076
 PB Royal Society of Chemistry
 DT Journal
 LA English
 AB A stilbenophane and protonated azobenzenophanes ("pseudo-stilbenes") with four -CH₂-S-CH₂- bridges in all meta-positions were synthesized. The spectroscopic and photochem. properties were investigated: excited dimer absorption spectra and for the stilbenophane also emission spectra were observed. Photochem. reactions could be identified as the [2+2] photocycloaddn. for the stilbenophane; the nature of the photoproducts in the case of pseudo-stilbenes could not be established. Photo-isomerizations could not be observed which gives a neg. answer to the title question.


RX(1) OF 63



RX(8) OF 63 - 2 STEPS



RX(15) OF 63 - 3 STEPS




NOTE: 3) Heck reaction

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
AN 136:37401 CASREACT
TI Process for the preparation of bromoisophthalic acid or derivatives thereof
IN Nagai, Masaki; Suzuki, Hideo; Hashiba, Isao
PA Nissan Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001094289	A1	20011213	2001WO-JP04532	20010530
	W: CN, KR, US				
	RW: DE, FR, GB, NL				
EP---	1293495	A1	20030319	2001EP-0934410	20010530
	R: DE, FR, GB, NL				
	JP2002060370	A	20020226	2001JP-0167799	20010604
	US2004015010	A1	20040122	2002US-0296500	20021125
	US---6855845	B2	20050215		
PRAI	2000JP-0167511		20000605		

2001WO-JP04532 20010530
 OS MARPAT 136:37401
 GI



AB This document discloses a process for preparing bromoisophthalic acid compds., particularly 5-bromoisophthalic acid compds. and 4,5-dibromoisophthalic acid compds., by brominating an isophthalic acid compound of the general formula I (wherein R1 and R2 are each independently hydrogen or C1-6 alkyl) with bromine in a solvent containing sulfur trioxide. The title compds. are pharmaceutical and agrochem. intermediates and additives for polymers. According to this process, bromoisophthalic acid compds., particularly 5-bromoisophthalic acid compds. and 4,5-dibromoisophthalic acid compds., can be prepared selectively using industrially inexpensive bromine.

RX(2) OF 2




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 135:107099 CASREACT
 TI Nonacid Nitration of Benzenedicarboxylic and Naphthalenecarboxylic Acid Esters
 AU Nose, Masatoshi; Suzuki, Hitomi; Suzuki, Hideo
 CS Department of Chemistry School of Science, Kwansei Gakuin University, Nishinomiya, 662-8501, Japan
 SO Journal of Organic Chemistry (2001), 66(12), 4356-4360
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 AB When treated with nitrogen dioxide in the presence of ozone and a catalytic amount of iron(III) chloride in inert organic solvent at -10 to +5 °C, benzenedicarboxylic acid diesters underwent smooth nitration to give the corresponding mononitro derivs. in good yield (Kyodai nitration). Naphthalenecarboxylic acid esters and naphthalene-1,8-dicarboxylic acid diester were similarly nitrated in the absence of catalyst to give the expected nitro compds. Different from conventional nitration based on the combined use of concentrated nitric and sulfuric acids, no hydrolytic cleavage of the ester function was observed under these conditions. The isomer distribution has been determined for the nitration of naphthalenecarboxylic acid esters and spectral data were collected for less common nitro derivs. A unique changeover of the orientation mode observed in the Kyodai nitration


of the diester, from the initial exclusive meta to the final meta/para, has been discussed in terms of the competition between the electrophilic substitution process involving the nitronium ion (NO_2^+) and the addition-elimination sequence involving the nitrogen trioxide radical ($\bullet\text{NO}_3$).

RX(2) OF 7



NOTE: regioselective, optimization study

RX(7) OF 7




NOTE: regioselective, optimization study



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
AN 134:340634 CASREACT
TI Synthesis of fluorescent stilbene and tolan rotaxanes by Suzuki coupling
AU Stanier, Carol A.; O'Connell, Michael J.; Anderson, Harry L.; Clegg, William
CS Department of Chemistry, University of Oxford, Oxford, OX1 3QY, UK
SO Chemical Communications (Cambridge, United Kingdom) (2001), (5), 493-494
CODEN: CHCOFS; ISSN: 1359-7345
PB Royal Society of Chemistry
DT Journal
LA English
AB Highly fluorescent stilbene and tolan cyclodextrin [2]rotaxanes have been synthesized in good yield using aqueous Suzuki coupling, and the crystal structure of one of these rotaxanes has been determined

RX(6) OF 7




RX(6) OF 7




4 Na
50%


RX(6) OF 7



RX(7) OF 7




RX(7) OF 7



1. Pd(OAc)₂, Na₂CO₃, Water
 2. Na₂CO₃, Water
 3. HCl
 4. Na₂CO₃, Water

MULTI
PAGE
IMAGE +
338793-49-0
73%

RX(7) OF 7



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 134:310986 CASREACT
 TI Preparation of dialkyl 5-bromoisophthalates by regioselective bromination
 IN Suzuki, Hideo; Nagai, Masanori; Myojo, Tomohiro; Hashiba, Isao
 PA Nissan Chemical Industries, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP2001122823	A	20010508	1999JP-0300591	19991022

PRAI 1999JP-0300591 19991022

OS MARPAT 134:310986

AB Title compds. are prepared by bromination of m-R2O2CC6H4CO2R1 (R1, R2 = C1-10 alkyl) by N-bromoisocyanuric acid (I) or its mono-Na or -K salt in strong acids. Di-Me isophthalate was brominated by I mono-Na salt in H2SO4 at 40-45° for 8 h to give 83.9% di-Me 5-bromoisophthalate.

RX(1) OF 1



NOTE: regioselective

L8 ANSWER 13 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 133:89275 CASREACT

TI Synthesis of sodium 3,5-dimethoxycarbonyl benzene sulfonate

AU Jiang, Jianping

CS Yangzhou Organic Chemical Plant, Yangzhou, 225003, Peop. Rep. China

SO Huagong Shikan (2000), 14(5), 21-23

CODEN: HUSHFT; ISSN: 1002-154X


PB Huagong Shikan Zazhishe

DT Journal

LA Chinese


AB The title compound, Na 3,5-dimethoxycarbonyl benzene sulfonate (SIPM) used as dye modifying agent for polyester was synthesized with 71.9% yield from isophthalic acid by sulfonation with H₂SO₄.SO₃, esterification with CH₃OH, and neutralization with NaOH or Na₂CO₃. The effects of reacting time, temperature, and ratio of raw materials on sulfonation ratio and esterification ratio were studied. The optimum reacting conditions were: sulfonating temperature 180°, reacting time 7 h, SO₃:IPA 1.1:1 (mol ratio), esterifying temperature 60-70°, reacting time 2-4 h, CH₃OH:IPA 4-5:1, and neutralizing temperature 15-20°.

RX(1) OF 6




NOTE: 150.degree., 7 h

RX(4) OF 6 - 2 STEPS



NOTE: 1) 150.degree., 7 h, 2) 60.degree.-70.degree., 2-4 h


RX(6) OF 6 - 3 STEPS



NOTE: 1) 150.degree., 7 h, 2) 60.degree.-70.degree., 2-4 h, 3) 15.degree.-20.degree.

L8 ANSWER 14 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 129:289936 CASREACT
 TI Preparation of dialkyl aminophthalates as intermediates for pharmaceuticals and dyes
 IN Suzuki, Hideo; Suzuki, Hitomi
 PA Nissan Chemical Industries, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--10251211	A	19980922	1997JP-0058915	19970313
PRAI	1997JP-0058915		19970313		
OS	MARPAT 129:289936				
GI					



AB The title compds. I [R1, R2 = alkyl, cycloalkyl] are prepared by nitration of dialkyl phthalates by nitrogen oxide and ozone, followed by reduction of the nitro compds. Thus, a mixture of ozone and oxygen was introduced into a mixture of di-Me isophthalate 3.88 g, N2O4 4.6 g, and FeCl3 0.01 g in 1,2-dichloroethane 40 g at 5° during 2.5 h to give, after workup,


di-Me 5-nitroisophthalate (II) in 88% yield. Hydrogenation of II 4.57 g in 1,2-dimethoxyethane containing 5% Pd/C 4.6 mg under hydrogen (5 kg/cm²) gave di-Me 5-aminoisophthalate in 86% yield.

RX(2) OF 3



NOTE: 2.5 h at 5.degree.

RX(3) OF 3 - 2 STEPS



NOTE: 1) 2.5 h at 5.degree.

L8 ANSWER 15 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 128:321458 CASREACT

TI Preparation of dialkyl 5-bromoisophthalates

IN Suzuki, Hideo; Hashiba, Isao

PA Nissan Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF


DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--10114712	A	19980506	1996JP-0272065	19961015
	JP---3911732	B2	20070509		
PRAI	1996JP-0272065		19961015		
OS	MARPAT 128:321458				
AB	Title compds. are prepared by bromination of 1,3-R2O2CC6H4CO2R1 (R1, R2 = C1-10 alkyl) with N-bromoimides as bromination agents in strong acid solvents. M-C6H4(CO2Me)2 was treated with N-bromosuccinimide in 97% H2SO4 at 40° for 8 h to give 85.6% di-Me 5-bromoisophthalate.				

RX(1) OF 1



L8 ANSWER 16 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 125:10318 CASREACT
 TI Synthesis of 2,6-dicyano-4-nitroaniline
 AU Xie, Yunging; Lian, Yieliang
 CS Dep. Environmental Eng., Qingdao Coll. Architecture Eng., Tsingtao, Peop.
 Rep. China
 SO Huaxue Shiji (1996), 18(2), 124-125
 CODEN: HUSHDR; ISSN: 0258-3283
 PB Huagongbu Huaxue Shiji Keji Qingbao Zhongxinzhuan
 DT Journal
 LA Chinese
 AB The title compound was prepared from isophthalic acid by nitration, cyanation, and amination.


RX(1) OF 6



NOTE: 6 H


L8 ANSWER 17 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 123:256091 CASREACT
 TI Arranging coordination sites around cyclotrimeratrylene
 AU Wytko, Jennifer A.; Weiss, Jean
 CS lab. d'Electrochim. Chim. Phys. Corps Solide, Univ. Louis Pasteur,
 Strasbourg, 67000, Fr.
 SO Journal of Inclusion Phenomena and Molecular Recognition in Chemistry
 (1994), 19(1-4), 207-25
 CODEN: JIMCEN; ISSN: 0923-0750
 PB Kluwer
 DT Journal
 LA English
 AB This article describes the attachment of coordination sites around a rigid matrix: cyclotrimeratrylene (CTV). The synthetic approaches leading to these new ligands possessing pyridines and bipyridines as coordinating sites are discussed and full synthetic details are given. One expanded CTV derivative bearing three 3-pyridyl groups has been characterized by X-ray crystallog. and the structure shows that the conformation adopted by the CTV matrix is appropriate for the coordination of transition metals, and inclusion of a range of mols. in the hydrophobic pocket.

RX(1) OF 95



L8 ANSWER 18 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 120:298430 CASREACT
 TI Dinitrogen pentoxide-sulfur dioxide, a new nitration system
 AU Bakke, Jan M.; Hegbom, Ingrid
 CS Norweg. Inst. Technol., Univ. Trondheim, Trondheim, N-7034, Norway
 SO Acta Chemica Scandinavica (1994), 48(2), 181-2
 CODEN: ACHSE7; ISSN: 0904-213X
 DT Journal
 LA English
 AB Nitration of pyridine and 2- and 3-methylpyridine with N_2O_5 in SO_2 solvent afforded 3-nitropyridine (60%), 2-methyl-5-nitropyridine:2-methyl-3-nitropyridine = 91:9 (69%), and 4-methyl-3-nitropyridine (51%); these reactants were inert under standard $\text{HNO}_3/\text{H}_2\text{SO}_4$ conditions. $\text{N}_2\text{O}_5/\text{SO}_2$ was also effective at nitration of isophthalate esters to 5-nitroisophthalate esters.

RX(2) OF 5




L8 ANSWER 19 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 120:163992 CASREACT
 TI Nitration system, and process for nitrating aromatic and hetero aromatic compounds
 IN Bakke, Jan; Hegbom, Ingrid
 PA Norsk Hydro A/S, Norway
 SO PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO---9323352	A1	19931125	1993WO-NO00065	19930423
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
NO---9300959	A	19931109	1993NO-0000959	19930317
NO----174462	B	19940131		

NO----174462 C 19940511
 AU--9340232 A 19931213 1993AU-0040232 19930423
 PRAI 1992NO-0001825 19920508
 1993NO-0000959 19930317
 1993WO-NO00065 19930423

AB The invention relates to a new nitration system, comprising N2O5 dissolved in liquid SO2. The invention also relates to a process for nitrating aromatic and hetero aromatic compds. using the new system. This process is particularly favorable for nitration of aromatic compds. that are unstable under acidic conditions. 2-Methylpyridine was added slowly to a solution of 25 mmol N2O5 in 25 mL SO2 at -78° and the mixture was warmed to -11° in 2 h and stirred for another 2 h, the reaction mixture was poured over ice, the aqueous solution was made basic with saturated NaHCO3 solution and extracted with CH2Cl2 to give 69% 2-methyl-5-nitropyridine, vs. 5% with nitration by HNO3/H2SO4. Also nitrated were quinoline, isoquinoline thiophene derivs. and dialkyl isophthalates.

RX(1) OF 5



NOTE: -78 to -11.degree.

L8 ANSWER 20 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 119:8240 CASREACT

TI Aqueous periodate oxidation of aromatic and aliphatic carboxylic acid disulfides

AU Evans, Brian J.; Doi, Joyce Takahashi; Musker, W. Kenneth

CS Dep. Chem., Univ. California, Davis, CA, 95616, USA

SO Phosphorus, Sulfur and Silicon and the Related Elements (1992), 73(1-4), 5-13


CODEN: PSSLEC; ISSN: 1042-6507

DT Journal


LA English

AB The water-soluble carboxylic acid-functionalized aromatic disulfides, 3,3'-dithiodibenzoic acid and 5,5'-dithiodiisophthalic acid [5,5'-dithiobis(1,3-benzenedicarboxylic acid)] were prepared and their rates of periodate oxidation to the sulfonic acids were determined. The reaction is first order in each of the reactants which indicates that the slow step is the initial oxidative cleavage step. These aromatic disulfides are oxidized to the sulfonic acids 4-8 times more slowly than a typical aliphatic disulfide. In all cases, water solubility of the disulfide is of prime importance. The periodate oxidation of two aliphatic carboxylic acid analogs were also examined, however, in these cases, the reactions were multiphasic and intermediate thiosulfonates were observed by 1H NMR along with the sulfonic acids.


RX(2) OF 7



RX(3) OF 7



RX(7) OF 7 - 2 STEPS



NOTE: 2) ZN/HCL

L8 ANSWER 21 OF 24 CASREACT COPYRIGHT 2007 ACS on STN

AN 117:69577 CASREACT

TI Nontoxic sulfonation catalyst for the manufacture of 5-sulfoisophthalic acid

IN Vorel, Milan

PA Czech.

SO Czech., 3 pp.

CODEN: CZXXA9

DT Patent


LA Czech

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS----265300	B1	19891013	1988CS-0004400	19880623
PRAI	1988CS-0004400		19880623		


AB In manufacturing the title compound (I) by sulfonation of isophthalic acid with fuming H₂SO₄, the reaction was accelerated by using 0.00001-0.1, preferably 0.004-0.007 mass % of SiO₂, as a nontoxic catalyst. Thus, 80 g SiO₂ was added to a mixture of 1225 kg fuming H₂SO₄ (25% free SO₃) and 300 kg isophthalic acid, and the whole was stirred and heated for 1 h at 190°. The mixture was cooled to 160°, mixed with 850 L of combined mother liquor and washings from a previous conversion of I to I-Na salt, and the whole cooled to 25° to give 589 g product containing 88% I.

RX(1) OF 2




NOTE: nontoxic catalyst

RX(2) OF 2




NOTE: nontoxic catalyst

L8 ANSWER 22 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 106:157944 CASREACT
 TI Synthesis and spectral characterization of blue azobenzene dyes
 AU Thiel, W.; Mayer, R.; Jauer, E. A.; Modrow, H.; Dost, H.
 CS Sek. Chem., Tech. Univ. Dresden, Dresden, Ger. Dem. Rep.
 SO Journal fuer Praktische Chemie (Leipzig) (1986), 328(4), 497-514
 CODEN: JPCEAO; ISSN: 0021-8383
 DT Journal
 LA German
 GI



AB Fifty-three donor-acceptor-substituted azo dyes (I, A = H, NHAc, NHCOEt, NHBz, NHCObu; B = H, OMe, R = Me, Et, Pr, CH₂CH₂OH, CH₂CH₂OAc; X = NO₂, CO₂Et, COSEt, CN, Br; Y = Cl, Br, I, CN, NO₂; Z = Cl, Br, I, CONH₂, SO₂Me, CN) were prepared by diazo coupling or halogen-CN exchange. The preparation of the precursor amines and couplers was also described. I have blue shades on polyester fibers.

RX(4) OF 61




L8 ANSWER 23 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 105:114750 CASREACT

TI Dimethyl 5-nitroisophthalate
 IN Lixandru, Tatiana; Saidac, Serban Gheorghe; Pastravanu, Mariana; Vasiliu Silvia; Mazilu, Ioan; Wagner, Luminita Eugenia
 PA Combinatul Chimic, Giurgiu, Rom.
 SO Rom., 2 pp.
 CODEN: RUXXA3
 DT Patent
 LA Romanian
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RO-----88168	B1	19851230	1983RO-0112310	19831012
PRAI	1983RO-0112310		19831012		

AB Di-Me isophthalate is nitrated with a mixture of H₂SO₄ (d. 1.84) and HNO₃ (d. 1.5) at 15-20°. The mixture is heated to 40°, to give the title compound in 94-96% yield at 95-99% purity. The product is a dye intermediate.


RX(1) OF 1



L8 ANSWER 24 OF 24 CASREACT COPYRIGHT 2007 ACS on STN
 AN 40:37261 CASREACT
 TI The synthesis of potential antimalarials. Some substituted N-phenylsulfonamides
 AU Senear, A. E.; Rapport, M. M.; Mead, J. F.; Maynard, J. T.; Koepfli, J. B.
 CS Calif. Inst. of Technol., Pasadena
 SO Journal of Organic Chemistry (1946), 11, 378-83
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA Unavailable
 AB Some substituted N-phenylsulfonamides of the formula p-RC₆H₄SO₂NHC₆H₂R'R''(3,4,5) (I) are synthesized to be tested as antimalarials. When 28 g. 3,5-(NO₂)₂C₆H₃NH₂ (II) in 200 cc. pyridine is treated with 55 g. p-AcNHC₆H₄SO₂Cl (III), added in small portions with cooling and stirring, the mixture kept at room temperature for 1 h., and then heated on a steam bath for 15 min., 93% N₄-acetyl-N₁-(3,5-dinitrophenyl)sulfanilamide (IV), m. 280-1° (decomposition), is obtained. Saponification of the Ac group in IV by refluxing 55 g. with 750 cc. EtOH and 220 cc. concentrated HCl for 2 h., gives 90% N₁-(3,5-dinitrophenyl)sulfanilamide (I, R = NH₂, R', R'' = NO₂, R'' = H) (SN 3863), crystals from EtOH, m. 214-15°. Reduction of 3,5-Br₂C₆H₃NO₂ at 50° and 50 lb. in the presence of Raney Ni gives 86% 3,5-Br₂C₆H₃NH₂ (V), m. 47.5-50.5°. V and III give 93% N₄-acetyl-N₁-(3,5-dibromophenyl)sulfanilamide which, when saponified, gives N₁-(3,5-dibromophenyl)sulfanilamide (I, R = NH₂, R', R'' = Br, R'' = H) (SN 187), m. 154-5°. Catalytic reduction of the Ac derivative of 2,6-dibromo-4-nitroaniline, prepared in 96% yield according to Mohlau and Uhlmann (Ann. 289, 94(1896)) gives 64% 2,6-dibromo-4-aminoacetanilide, m. 246.5-8.5°, which, when coupled with III, gives 81% N₄-acetyl-N₁-(3,5-dibromo-4-acetamidophenyl)sulfanilamide (VI), m. 236-8°. Saponification of VI gives 76% N₁-(3,5-dibromophenyl-4-acetamidophenyl)sulfanilamide, m. 210-13°. 2,6-Dibromo-p-

phenylenediamine and III give N4-acetyl-N1-(3,5-dibromo-4-aminophenyl)sulfanilamide, m. 232-3.5°, which when saponified by refluxing with EtOH-HCl for 1 h. gives 85% N1-(3,5-dibromo-4-aminophenyl)sulfanilamide (SN 3864), m. 176-7°. When 44.8 g. p-Cl₆H₄NO₂, 40 cc. NHMe₂, and 200 cc. EtOH are heated for 4 h. at 160°, 88% p-O₂NC₆H₄NMe₂ (VII), m. 163-6°, is obtained. Bromination of VII gives 30% N-methyl-2,6-dibromo-4-nitroaniline, yellow crystals, m. 111-13°, which, when reduced, gives 54% N-methyl-2,6-dibromo-p-phenylenediamine (VIII), m. 103-4°, VIII and III give 92% N4-acetyl-N1-(3,5-dibromo-4-methylaminophenyl)sulfanilamide m. 220-1.5°, which, when saponified, gives 80% N1-(3,5-dibromo-4-methylaminophenyl)sulfanilamide (I, R = NH₂, R', R''' = Br, R'' = NHMe) (SN 3865), m. 147-8.5°. 3,5-Dibromo-4-iodo-1-nitrobenzene (IX), prepared in the same way as 3,4,5-triiodo-1-nitrobenzene (cf. Niemann and Redemann, C.A. 35, 5475.2) in 75% yield, m. 150.5-2.5°. When 40.7 g. IX and 15 cc. NHMe₂ are heated in 80 cc. BuOH in a sealed tube at 120-30° for 7 h., 85% 3,5-dibromo-4-dimethylamino-1-nitrobenzene, golden plates, m. 102-3.5°, is formed which, when catalytically reduced, gives 100% 3,5-dibromo-4-dimethylaminoaniline (X). Because X is very unstable, it is immediately coupled with III to give 95% N4-acetyl-N1-(3,5-dibromo-4-dimethylaminophenyl)sulfanilamide, m. 252-3°; Ac-free analog (I, R = NH₂, R', R''' = Br, R'' = NMe₂) (SN 3866), 79% yield, platelets from EtOH, m. 194.5-6°. m-NCC₆H₄NH₂ and p-O₂NC₆H₄SO₂Cl (XI) give 77% 3'-cyano-4-nitrobenzenesulfonanilide (XII), prisms from AcOH, m. 198.5-9.5°. Reduction of XII with Fe and HCl on a steam bath for 6 h. gives 90% N1-(3-cyanophenyl)sulfanilamide (I, R = NH₂, R' = CN, R'', R''' = H) (SN 6947), m. 191-2°. 5-Nitroisophthalic acid, m. 254-8°, is prepared in 70-5% yield by heating 120 g. isophthalic acid with 600 cc. fuming HNO₃ (d. 1.6) for 8 h. When an intimate mixture of 10 g. 5-nitroisophthalamide and 13 g. P2O₅ is heated for 8 h. at 240-50°, 46% 3,5-(NC)₂C₆H₃NO₂, yellow prisms, m. 203.5-5.5°, is obtained which, on reduction with SnCl₂ in HCl, gives 41% 3,5-(NC)₂C₆H₃NH₂ (XIII), needles, m. 192-3°. XIII and XI give 91% 3',5'-dicyano-4-nitrobenzenesulfonanilide, m. above 300°, which, on reduction with Fe and HCl, gives 76% N1-(3,5-dicyanophenyl)sulfanilamide (I, R = NH₂, R', R''' = CN, R'' = H) (SN 6946), greenish yellow prisms, m. 227.5-8.5°. When 20 g. V is reacted with 19.6 g. p-NCC₆H₄SO₂Cl in pyridine, 93% 4-cyano-3',5'-dibromobenzenesulfonanilide (XIV), plates or flat prisms, m. 196.5-7.5°, is obtained. Catalytic reduction of 37.5 g. XIV in 920 cc. absolute EtOH containing 0.112 mol. HCl with 3 g. PtO₂ at 1 atmospheric for 5 h. gives 30.4 g. 4-aminomethyl-3',5'-dibromobenzenesulfonanilide-HCl (I, R = CH₂NH₂, R', R''' = Br, R'' = H) (SN 8828), crystallizing with 1 mol. H₂O, large flat prisms, m. 273-4° (decomposition); free base, prisms, m. 214.5-15.5°. All m.ps. are corrected

RX(1) OF 1



NOTE: Classification: C-Nitration; Regioselective; # Conditions: fuming HNO₃; heat 8h

=> d his

(FILE 'HOME' ENTERED AT 14:21:21 ON 07 JUN 2007)

FILE 'CASREACT' ENTERED AT 14:21:33 ON 07 JUN 2007

L1 STR
L2 45 L1
L3 STR L1
L4 23 L3
L5 352 L3 FULL
L6 STR L3
L7 1 L6 SAM SUB=L5
L8 24 L6 FULL SUB=L5

FILE 'STNGUIDE' ENTERED AT 14:29:38 ON 07 JUN 2007

FILE 'CASREACT' ENTERED AT 14:32:10 ON 07 JUN 2007

=>

=> b reg

FILE 'REGISTRY' ENTERED AT 15:26:49 ON 07 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4
 DICTIONARY FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l10

L9 STR



REP G1=(1-20) C

VAR G2=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L10 35 SEA FILE=REGISTRY SSS FUL L9

100.0% PROCESSED 25388 ITERATIONS

35 ANSWERS

SEARCH TIME: 00.00.01

=> b hcap

FILE 'HCAPLUS' ENTERED AT 15:26:59 ON 07 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field. (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007 VOL 146 ISS 24
 FILE LAST UPDATED: 6 Jun 2007 (20070606/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d bib abs hitstr retable 3 5

L11 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:117097 HCAPLUS
 DN 144:212810
 TI Preparation of macrocyclic β -secretase inhibitors
 IN Stamford, Andrew W.; Huang, Ying; Li, Guoqing; Strickland, Corey O.; Voigt, Johannes H.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2006014944	A1	20060209	2005WO-US26468	20050726
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA---2575340	A1	20060209	2005CA-2575340	20050726
US2006040948	A1	20060223	2005US-0189346	20050726
EP---1781644	A1	20070509	2005EP-0776414	20050726
R:				
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI 2004US-591899P	P	20040728		
2005WO-US26468	W	20050726		
OS CASREACT 144:212810; MARPAT 144:212810				
GI				



AB Macrocyclic lactams, such as I [R1 = nitrogen containing heterocyclyl, such as piperazinyl; W = heterocyclene or N(R5)C(O)W1, R5 = H, alkyl, cycloalkyl, aryl, heteroaryl, W1 = arylene, heteroarylene, heterocyclene, cycloalkylene; X = O, S, NH, C(R5); Y = (CH₂)_n, n = 0-3; Z = arylene, heteroarylene, heterocyclene, cycloalkylene] were prepared for use in pharmaceutical compns. as β -secretase inhibitors useful for the treatment of cognitive or neurodegenerative diseases, such as Alzheimer's disease. These macrocyclic lactams were also claimed for use in combination with other therapeutic agents selected from HMG-CoA reductase inhibitors, γ -secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies. The cholinesterase inhibitors, wherein said cholinesterase inhibitor is acetylcholinesterase or butyrylcholinesterase, can be selected from the group consisting of tacrine, donepezil, rivastigmine, galantamine, pyridostigmine and neostigmine. The nonsteroid antiinflammatory agents can be selected from diclofenac, diflunisal, etodolac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib or rofecoxib. The HMG-CoA reductase inhibitors can be selected from atorvastatin, lovastatin, simvastatin, pravastatin, fluvastatin or rosuvastatin. The N-methyl-D-aspartate receptor antagonist can be memantine. Thus, macrocyclic lactam II was prepared was prepared via multistep synthetic sequence starting from Cl(CH₂)₄OH, Me(CH₂)₂NH₂, MeOCOC₆H₄-3-CO₂H, L-tyrosine Me ester and piperazinone. The prepared macrocyclic lactams were assayed for β -secretase inhibitory activity.

IT 875762-75-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic β -secretase inhibitors for the treatment of cognitive or neurodegenerative diseases and for use in combination with other therapeutic agents)

RN 875762-75-7 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[hydroxy[3-oxo-4-(phenylmethyl)-2-piperazinyl]methyl]-16-propyl-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 875762-94-0P 875762-96-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of macrocyclic β -secretase inhibitors for the treatment of cognitive or neurodegenerative diseases and for use in combination with other therapeutic agents)

RN 875762-94-0 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),13,18,20-heptaene-2,17-dione, 8-fluoro-4-(hydroxymethyl)-16-propyl-, (4S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 875762-96-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 2-[[[(4S)-8-fluoro-2,17-dioxo-16-propyl-11-oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaen-4-yl]hydroxymethyl]-3-oxo-4-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Pulley, S	2002			WO----02100399 A	HCAPLUS
Pulley, S	2002			WO----02100856 A	HCAPLUS

L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:964186 HCAPLUS

DN 138:24959

TI Preparation of macrocycles useful in the treatment of Alzheimer's disease

IN Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.; Jacobs, Jon S.

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 173 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002100399	A1	20021219	2002WO-US18719	20020612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2450167	A1	20021219	2002CA-2450167	20020612
	AU2002315098	A1	20021223	2002AU-0315098	20020612
	EP---1395257	A1	20040310	2002EP-0742038	20020612
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR2002010391	A	20040615	2002BR-0010391	20020612
	JP2005505506	T	20050224	2003JP-0503220	20020612
	US2003236240	A1	20031225	2002US-0170331	20020613
	US---7067507	B2	20060627		
	US2006003978	A1	20060105	2005US-0208382	20050819
PRAI	2001US-297505P	P	20010612		
	2001US-333082P	P	20011119		
	2002WO-US18719	W	20020612		
	2002US-0170331	A3	20020613		
OS	MARPAT 138:24959				
GI					



AB Macrocycles I [U is (un)substituted 1,3-dihydroxypropyl, 1-hydroxy-2-aminoethyl, oxiranyl, or 2-oxo-1,3-dioxolan-4-yl; V is (CH₂)₀₋₆; A, B, Y are (un)substituted alkylene or alkenylene or rings of defined structure; D is CH₂, CO, or SO₂; X is absent, O, or an imino group; Z is absent, O, S, an imino group, CO, O₂C, CO₂, NHCO, or CONH] were prepared for treating Alzheimer's and similar diseases characterized by the deposition of Aβ peptide in a mammal. Thus, macrocycle II was prepared by a multistep sequence involving reaction of 1-(allyloxy)-5-fluorobenzene with 2-(2,2-dimethyl[1,3]dioxolan-4-yl)aziridine-1-carboxylic acid tert-Bu ester.

IT 477954-35-1P 477954-37-3P 477954-39-5P
 477954-41-9P 477954-43-1P 477954-44-2P
 477954-46-4P 477954-48-6P 477954-52-2P
 477954-55-5P 477954-56-6P 477954-57-7P
 477954-58-8P 477954-60-2P 477954-61-3P
 477954-62-4P 477954-64-6P 477954-66-8P
 477954-68-0P 477954-69-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocycles useful in treatment of Alzheimer's disease)

RN 477954-35-1 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-37-3 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-39-5 HCAPLUS


CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-41-9 HCAPLUS
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-43-1 HCAPLUS
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[5-ethyl-3-pyridinyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 477954-44-2 HCAPLUS
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[3-ethylphenyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-46-4 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-48-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-52-2 HCAPLUS

11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-55-5 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[5-ethyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-56-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyloxy)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-57-7 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyloxy)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-58-8 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-60-2 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-61-3 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(5-ethyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-62-4 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-64-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-66-8 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-68-0 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-(2-oxazolyl)-, (4S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-69-1 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[5-ethyl-3-pyridinyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Fairlie, D	1996			WO-----9616950 A	HCAPLUS
Fairlie, D	2000	7	1271	JOURNAL OF MEDICINAL	

=> d his 19-

FILE 'REGISTRY' ENTERED AT 14:46:45 ON 07 JUN 2007
 ACT J476C1/A

L9 STR
 L10 35 SEA FILE=REGISTRY SSS FUL L9

FILE 'HCAPLUS' ENTERED AT 14:47:02 ON 07 JUN 2007
 L11 5 L10

=>